menu
    • menu
    [{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Stem cell therapy","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0.01,"dosageForm":"","sponsorNew":"Rinri Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Stem cell therapy","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Rinri Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Innovate UK"}]

    Find Clinical Drug Pipeline Developments & Deals by Rinri Therapeutics

    Menu

    Rinri Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rinri Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Rinri Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stem cell therapy

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Preclinical

                            Sponsor : Innovate UK

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Rinri Therapeutics Secures Innovate UK Funding Grant for £3.2m Project to Advance its Novel Cell-Based Therap...

                            Details : This grant will fund a £3.2 million project to further develop Rinri’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL) an area / a condition where there remains a significant global unmet need.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 13, 2021

                            Lead Product(s) : Stem cell therapy

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Preclinical

                            Sponsor : Innovate UK

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rinri Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Rinri Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stem cell therapy

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $14.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Rinri Therapeutics Raises £10M from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Ther...

                            Details : The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 20, 2021

                            Lead Product(s) : Stem cell therapy

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $14.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth